Pharma BD Deal Intelligence

LEO Pharma A/S / Tanabe Pharma Corporation

2026 · Asset Purchase · $435M · Pending

LEO Pharma agreed to acquire global rights to Tanabe Pharma Corporation's dersimelagon (MT-7117), an investigational once-daily oral melanocortin 1 receptor (MC1R) agonist, for up to USD 435 million in upfront and near-term milestone payments, plus potential downstream milestones and tiered royalties on net sales. Dersimelagon is in development for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), rare genetic disorders causing severe sunlight-induced skin pain. A US NDA was submitted in June 2026 under Fast Track and Orphan Drug designations, supporting a potential 2027 launch. The transaction is expected to close in H2 2026. The split between upfront and near-term milestones was not disclosed.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals  ·  LEO Pharma A/S deals